Brind.

The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.

2 reports, 2 independent Updated Sep 7
Gone quiet
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Insider sale disclosed in SEC filing involving Bristol-Myers Squibb.Sub-event
  2. FDA approved Zenbexus oral therapy for multiple myeloma; insider trading disclosed.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped